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A Case of Severe Factor VIII Deficiency 
 
Onyinyechukwu Ochi MD, Stanlies D’Souza MD 
Department of Anesthesiology at Baystate Medical Center/University of Massachusetts Medical School 
Discussion 
Hemophilia A (factor VIII deficiency) is an X-linked coagulation factor 
disorder associated with bleeding of variable severity, from life-threatening 
to clinically silent. 1  
 
Factor VIII deficiency/Hemophilia A affects 1 in 5000 to 10,000 males; 
roughly 60 percent have severe disease, with factor VIII activity less than 
1 percent of normal.1,2 
 
The factor VIII gene is located on the X chromosome. It is one of the 
largest known genes. It  circulates in plasma with von Willebrand factor. 
Cleavage of factor VIII by thrombin or factor Xa is necessary to activate 
factor VIII and allow it to participate in the intrinsic pathway. Activated 
factor VIII is inactivated by activated protein C in conjunction with 
proteins.3,4,5 
 
In patients with hemophilia with acute bleeding, the immediate goal is to 
raise the factor activity to a level sufficient to achieve hemostasis.2 
 
For severe bleeding, the factor activity level should be maintained above 
50 percent at all times. 
  
An initial dose of  50 units/kg to raise the factor VIII level to 100 percent 
should be given. The second and subsequent doses are given at intervals 
of approximately one half-life of the infused product for that patient. A 
typical half-life for standard half-life factor VIII products is approximately 8 
to 12 hours.2,3 
 
For patients who require perioperative factor administration, the initial 
dose should be timed to provide maximal coverage at the time of greatest 
bleeding risk (or, typically, 30 to 60 minutes before the procedure). The 
dose is calculated from the patient's weight, baseline factor level, desired 
factor level, volume of distribution, and presence of an inhibitor.2,5 
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Therapies other than factor replacement 1,2,4 
Therapies Use DOSAGES 
Tranexamic Acid 
(TXA) 
Inhibit fibrinolysis by inhibiting 
plasminogen activation in the 
fibrin clot, thereby enhancing 
clot stability. 
25 mg/kg every 6-8 hours 
Epsilon  
Aminocaproic 
Acid (EACA) 
Same as above 75-100 mg/kg every 6 hours, max 3-4g 
Desmopressin 
(DDAVP) 
Increases factor VIII level two-
four fold.  Not effective for 
patients with severe 
hemophilia A (Factor VIII 
activity <1%). 
0.3 mcg/kg (max, 20 mcg/kg), IV or nasal 
Factor Replacement 
 
Purified factor products are the 1st choice and 
should be used whenever possible to avoid 
potential transfusion-transmitted infection and 
transfusion reactions.2,4 
 
However, other blood products like 
Cryoprecipitate can also be used. One bag of 
Cryoprecipitate is made from approximately 250 
mL of fresh frozen plasma (FFP) and contains 
approximately 70 to 80 units of factor VIII in a 
volume of 30 to 40 mL (approximately 3 to 5 
units/mL).2  
 
FFP is deemed an inadequate choice for factor 
replacement  because 1mL of FFP contains 1unit 
of factor activity. A dose of 15 to 20 mL/kg will 
raise the factor VIII level by approximately 30 to 40 
percent. This amounts to lots of bags of FFP to 
get the desired  factor amount, which 
consequently exposes patient to possible fluid 
overload, transfusion infections and reactions.1,2 
Introduction3,5 
Hemophilia refers to an inherited 
bleeding disorder caused by deficiency of 
coagulation factor VIII (hemophilia A), 
factor IX (hemophilia B), or factor XI 
(hemophilia C). Hemophilia A and B are 
X-linked recessive diseases that present 
in male children of carrier females.3,4 
 
Hemophilia A – Inherited deficiency of 
factor VIII; an X-linked recessive 
disorder4.  
 
                     Case description  
Patient is a 5-year-old male with severe 
factor VIII deficiency initially diagnosed, at 
age 3, as severe oral bleeding following a 
lip laceration.  His factor VIII was less 
than 1%.  Consequently, patient had been 
on "on demand" replacement but, due to 
an increase in bleeds, is being switched 
to prophylaxis.  The main joints affected 
are the elbows, knees and ankles.  
Because of the increasing need for home 
factor infusion, a Port-A-Cath is being 
placed.  His disease is considered 
severe.  The known duration is 
approximately two years and is 
associated with spontaneous 
hemarthroses and bleeding.  It is 
ameliorated with factor replacement. 
Patient is to receive Recombinant factor 
VIII 500 units IV twice a week 
(approximately 18 U/kg). 
 
Before the procedure, patient received 
approximately 50 U/kg of recombinant 
factor VIII immediately before the port 
placement. He was intubated with an 
LMA and had no excessive bleeding 
during the procedure. 
Fig. 2.  Source: Managing  Your 
Hemophilia..  Copy right  © 
2016 by Saunders, an imprint of 
Elsevier, Inc.  Downloaded from 
ClinicalKey.  Accessed Sept. 22, 
2018.  
Fig. 1. Source:  Bhat R, Cabey 
W.  Evaluation and 
Management of Congenital 
Bleeding Disorders.6 
Downloaded from Clinical 
Key.  Accessed Sept 22, 2018.  
Conclusion 
 
• Perioperative management of Factor VIII deficiency, is dependent on 
the severity of the factor deficiency as well as the type of procedure 
being performed.1,3 
• Factor VIII replacement with recombinant Factor VIII, 30 minutes 
before surgery, is the preferred method of treatment; however, 
alternative forms of replacement, factor related and otherwise, can be 
implemented.2,4 
• Depending on the surgery, factor replacement should be given before 
and after surgery, as surgeries with a lot of blood loss deplete Factor 
VIII faster.2,3,5 
